Influence of abdominal obesity on heart structural and functional changes and possibility of their pharmacological correction in patients with arterial hypertension

Aim. To study clinical and epidemiological features of arterial hypertension (HT) combined with abdominal obesity (AO) and pharmacological correction of left ventricle myocardium structural and functional disorders. Material and methods. Single-stage epidemiological study was conducted in Novgorod region population (n=4840). All patients with HT were revealed and analyzed depending on age and gender. Patients with HT grade 2 were split in two groups. 124 women (aged 49,36 +/- 1,2 y.o.) and 126 men (aged 50,15 +/- 1,8 y.o.) with HT and AO were included in the first group. 127 women (aged 50,05 +/- 1,7 y.o.) and 125 men (aged 49,61 +/- 1,6 y.o.) with HT and normal body mass index were included in the second group. Anthropometric and echocardiography examination was performed before and after 1, 3 and 6 months of therapy (metoprolol, nebivolol, amlodipine, lisinopril). Results. High prevalence of HT was revealed: 44,4% in men and 48,7% in women. AO was observed 5,4 times more often in women than this in men (18,5% and 3,4%, respectively, p<0,001). Combination of HT and AO was also revealed 5,3 times more often in women than this in men (14,3% and 2,7%, respectively, p< 0,001). AO in patients with HT contributes to development of left ventricle concentric hypertrophy and diastolic dysfunction. Conclusion. Antihypertensive therapy does not prevent left ventricle hypertrophy and diastolic dysfunction in hypertensive patients with AO.